Keenova Therapeutics Presents New TERLIVAZ Clinical Data for Hepatorenal Syndrome at Digestive Disease Week 2026

Key Takeaways

• Keenova Therapeutics presents new clinical analysis of TERLIVAZ (terlipressin) for hepatorenal syndrome-acute kidney injury at Digestive Disease Week 2026
• The presentation expands clinical evidence for treating this rapidly progressive and challenging liver-kidney condition
• Data could advance understanding of HRS-AKI treatment options and support broader clinical adoption of terlipressin therapy

---

DUBLIN, May 1, 2026 — Keenova Therapeutics plc announced new clinical findings for TERLIVAZ® (terlipressin) in treating hepatorenal syndrome-acute kidney injury (HRS-AKI) will be presented at Digestive Disease Week (DDW) from May 2-5, 2026.

Clinical Evidence Expansion

The pharmaceutical company’s latest analysis focuses on hepatorenal syndrome-acute kidney injury, a serious complication affecting patients with advanced liver disease. HRS-AKI represents a rapidly progressive condition where liver dysfunction leads to kidney failure, creating urgent treatment challenges for healthcare providers.

“We are pleased to share these findings with the medical community, as they expand the clinical evidence and advance our understanding of this challenging and rapidly progressive condition,” said Dr. Marek Honczarenko, Executive Vice President at Keenova Therapeutics.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Treatment Landscape

TERLIVAZ received FDA approval as the first and only FDA-approved treatment specifically for HRS-AKI in adult patients. The drug works as a vasopressin analog that helps restore kidney function by improving blood flow to the kidneys in patients with liver cirrhosis.

The new clinical data presentation at DDW 2026 could strengthen the evidence base for terlipressin use, potentially influencing treatment guidelines and physician adoption rates. Hepatorenal syndrome affects approximately 20-50% of patients with decompensated cirrhosis, representing a significant unmet medical need.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Conference Significance

Digestive Disease Week serves as one of the largest international gatherings of gastroenterologists, hepatologists, and related specialists. The conference provides a platform for sharing cutting-edge research and clinical developments in digestive health, making it an ideal venue for presenting HRS-AKI treatment advances.

The timing of this presentation aligns with growing clinical interest in specialized treatments for liver-kidney complications, as healthcare systems seek evidence-based solutions for complex patient populations.

---

Frequently Asked Questions

What is hepatorenal syndrome-acute kidney injury (HRS-AKI)?

HRS-AKI is a serious complication where patients with advanced liver disease develop rapid kidney failure, affecting 20-50% of patients with decompensated cirrhosis and requiring urgent medical intervention.

How does TERLIVAZ work for HRS-AKI treatment?

TERLIVAZ (terlipressin) is a vasopressin analog that helps restore kidney function by improving blood flow to the kidneys in patients with liver cirrhosis, and it’s the first FDA-approved treatment specifically for HRS-AKI.

When will the new clinical data be available?

The new TERLIVAZ clinical analysis will be presented at Digestive Disease Week from May 2-5, 2026, with detailed findings expected to be shared with the medical community during the conference.

Related coverage

• Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026
• Clinical Trials Outsourcing Market Size: 2026-2034 Growth Outlook
• Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context